載入...

Neoadjuvant Enzalutamide Prior to Prostatectomy

PURPOSE: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate micrometastases. We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Cancer Res
Main Authors: Montgomery, Bruce, Tretiakova, Maria, Joshua, Anthony M., Gleave, Martin, Fleshner, Neil, Bubley, Glenn J., Mostaghel, Elahe A., Chi, Kim N., Lin, Daniel W., Sanda, Martin, Novotny, William, Wu, Kenneth, Kantoff, Philip, Marck, Brett T., Plymate, Stephen, Balk, Steven P., Nelson, Peter S., Matsumoto, Alvin M., Lis, Rosina, Haas, Gabriel P., Krivoshik, Andrew, Hannah, Alison, Taplin, Mary-Ellen
格式: Artigo
語言:Inglês
出版: 2016
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570479/
https://ncbi.nlm.nih.gov/pubmed/28151719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1357
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!